8.85
+0.655(+7.99%)
Currency In USD
| Previous Close | 8.2 |
| Open | 8.21 |
| Day High | 8.85 |
| Day Low | 8.05 |
| 52-Week High | 18.9 |
| 52-Week Low | 8.05 |
| Volume | 2.64M |
| Average Volume | 2.58M |
| Market Cap | 864.52M |
| PE | -18.44 |
| EPS | -0.48 |
| Moving Average 50 Days | 9.97 |
| Moving Average 200 Days | 13.22 |
| Change | 0.66 |
If you invested $1000 in ARS Pharmaceuticals, Inc. (SPRY) since IPO date, it would be worth $354 as of November 10, 2025 at a share price of $8.85. Whereas If you bought $1000 worth of ARS Pharmaceuticals, Inc. (SPRY) shares 3 years ago, it would be worth $1,475 as of November 10, 2025 at a share price of $8.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may already have an auto-injector, but are looking for a sm
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
GlobeNewswire Inc.
Nov 03, 2025 7:23 PM GMT
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation to report results from real world data on the effectiveness of epinephrine nasa
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to a